Article thumbnail

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

By Robert M Berman, Michael E Thase, Madhukar H Trivedi, James A Hazel, Sabrina Vogel Marler, Robert D McQuade, William Carson, Ross A Baker and Ronald N Marcus
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3104689
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A new depression scale designed to be sensitive to change.
  2. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
  3. A rating scale for depression.
  4. (1989). A rating scale for drug-induced akathisia.
  5. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl.
  6. (1976). Abnormal Involuntary Movement Scale (AIMS). In:
  7. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report.
  8. (2000). American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 2nd ed.
  9. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
  10. (2003). Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebocontrolled trials. Schizophr Res.
  11. (2000). Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
  12. (2007). Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists. Psychopharmacol Bull.
  13. Changes in weight during a 1-year trial of fluoxetine.
  14. (1976). Clinical Global Impressions (CGI). In:
  15. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives.
  16. (2006). Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosom.
  17. Diagnosis and definition of treatment-resistant depression.
  18. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
  19. Effects of the antidepressant duloxetine on body weight: Analyses of 10 clinical studies.
  20. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice.
  21. (2006). Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry.
  22. (2002). Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry.
  23. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance.
  24. (2004). Overview of safety and tolerability of aripiprazole in acute mania. Paper presented at the annual meeting of the American Psychiatric Association,
  25. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163).
  26. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
  27. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study.